

**Monoclonal  
Antibodies  
Detecting  
Human  
Antigens**



# CD11c (B-Ly6)

Form	Catalog number
PerCP-Cy™5.5	658330
PE-Cy™7	652358
BV605	663807

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

## RESEARCH APPLICATIONS

Research applications include:

- Enumeration of monocytes and macrophages<sup>1</sup>
- Studies of complement receptors<sup>2</sup>
- Investigation into dendritic cell subsets in peripheral blood and lymphoid tissues<sup>3-6</sup>
- Immunophenotyping of leukemias and lymphomas<sup>7</sup>

## DESCRIPTION

### Specificity

The CD11c antibody specifically binds to a 150-kilodalton (kDa) type I integral membrane glycoprotein. The CD11c antigen is also known as p150, integrin alpha X (integrin  $\alpha$ X), and CR4.<sup>8</sup>

### Antigen distribution

The CD11c antigen is expressed on monocytes, macrophages, dendritic cells, granulocytes, neutrophils, NK cells, and certain subsets of T and B lymphocytes.<sup>2</sup> It is also expressed on hairy cell leukemias and on some acute myeloid leukemias.<sup>9,10</sup>

The CD11c antigen associates with CD18 (p95) to form the CD11c/CD18 heterodimer that binds to fibrinogen<sup>11</sup> and has been reported to be a receptor for iC3b, ICAM-1, and VCAM-1.<sup>2,12,13</sup> Reports indicate that CD11c/CD18 plays a role as an adhesion molecule that mediates cellular binding to ligands expressed on stimulated endothelium.<sup>14</sup>

### Clone

The CD11c antibody, clone B-Ly6,<sup>15</sup> is derived from the hybridization of X63 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with a cell suspension isolated from the spleen of a patient with hairy cell leukemia.<sup>10</sup>

### Composition

The CD11c antibody is composed of mouse IgG<sub>1</sub> heavy chains and kappa light chains.

### Product configuration

The following are supplied in buffer containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (µL) <sup>a</sup>	Amount provided (µg)	Total volume (mL)	Concentration (µg/mL)	Stabilizer	Preservative
PerCP-Cy5.5	50	20	13	1	13	Gelatin	0.1% Sodium azide
PE-Cy7	100	5	25	0.5	50	BSA	0.1% Sodium azide
BV605 <sup>b</sup>	100	5	100	0.5	200	BSA	0.09% Sodium azide

a. Volume required to stain 10<sup>6</sup> cells.  
b. BD Horizon Brilliant™ Violet 605

**For Research Use Only. Not for use in diagnostic or therapeutic procedures.**

**Becton, Dickinson and Company**  
BD Biosciences  
2350 Qume Drive  
San Jose, CA 95131 USA



## PROCEDURE

Visit our website ([bdbiosciences.com](http://bdbiosciences.com)) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

**CAUTION** Some PE-Cy7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


**CAUTION** Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

**CAUTION** For optimal results, use BD Horizon™ Brilliant Stain Buffer any time two or more BD Horizon Brilliant™ reagents are used in the same multicolor staining cocktail.

## REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm or 488 nm.

The BV605 conjugates are read off the violet laser using a 606/36 filter. Representative data analyzed with a BD FACSTM brand flow cytometer is shown in the following plots. The BV605 conjugate in the new formulation is shown in the second CD11c BV605-A vs SSC-A dot plot.



## HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

## WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection<sup>16,17</sup> and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Visit [regdocs.bd.com](http://regdocs.bd.com) to download the Safety Data Sheet.

## CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

## WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

## REFERENCES

1. Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. *The Leucocyte Antigen FactsBook*. 2nd ed. San Diego, CA: Academic Press; 1997.

2. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR<sub>4</sub>) activity resembling CR<sub>3</sub>. *J Clin Invest*. 1988;82:640-651.
3. Grouard G, Durand I, Filgueira L, Banchereau J, Liu YJ. Dendritic cells capable of stimulating T cells in germinal centres. *Nature*. 1996;384:364-367.
4. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. *Immunology*. 1994;82:487-493.
5. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. *Proc Natl Acad Sci USA*. 1997;94:12551-12556.
6. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. *J Immunol*. 1994;153:4016-4028.
7. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26:1908-1975.
8. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers*. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
9. Schwarting R, Stein H, Wang CY. The monoclonal antibodies  $\alpha$ S-HCL 1 ( $\alpha$ Leu-14) and  $\alpha$ S-HCL 3 ( $\alpha$ Leu-M5) allow the diagnosis of hairy cell leukemia. *Blood*. 1985;65:974-983.
10. Visser L, Shaw A, Slupsky J, Vos H, Poppema S. Monoclonal antibodies reactive with hairy cell leukemia. *Blood*. 1989;74:320-325.
11. Lishko VK, Yakubenko VP, Hertzberg KM, Grieninger G, Ugarova TP. The alternatively spliced  $\alpha$ <sub>E</sub>C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins  $\alpha$ <sub>M</sub> $\beta$ <sub>2</sub> and  $\alpha$ <sub>X</sub> $\beta$ <sub>2</sub>. *Blood*. 2001;98:2448-2455.
12. Frick C, Odermatt A, Zen K, et al. Interaction of ICAM-1 with  $\beta$ 2-integrin CD11c/CD18: Characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1. *Eur J Immunol*. 2005;35:3610-3621.
13. Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. *Arterioscler Thromb Vasc Biol*. 2011;31:160-166.
14. Stacker SA, Springer TA. Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. *J Immunol*. 1991;146:648-655.
15. Schmidt RE. Non-lineage/natural killer Section report: new and previously defined clusters. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:517-542.
16. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Fourth Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. CLSI document M29-A4.
17. Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. <https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>. Accessed March 12, 2019.

## PATENTS AND TRADEMARKS

BV605 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; or 8,354,239.

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

BD, the BD Logo, FACS, Horizon and Horizon Brilliant are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.